Abstract
The transepithelial transport of arginine vasopressin (AVP) across cultured rat alveolar epithelial cell monolayers was studied. At 0.1 nM donor [125I]AVP, the radiolabel flux measured in the apical-to-basolateral (AB) direction was about 10 times greater than that in the reverse (BA) direction. HPLC analyses of the basolateral receiver fluid collected at the end of these flux measurements showed that about 97% of total [125I]label represented subspecies of AVP, whereas the apical receiver fluid contained largely intact AVP (-85% of total [125I]label). Both donor fluids contained virtually no degradation products of AVP (>99%). In the presence of an excess 0.1 mM unlabeled AVP in the apical donor fluid, the Papp for radiolabeled AVP in the AB direction was decreased by ~68%, while the fraction of intact AVP in the basolateral receiver fluid was increased six-fold as compared to that observed at 0.1 nM [125I]AVP alone. Under this condition, the flux of intact AVP was approximately the same in both directions. When the concentration of apical camostat mesylate, an aminopeptidase inhibitor, was varied from 0 to 2 mM, the radiolabeled flux in the AB direction (with 0.1 nM [125I]AVP in the donor fluid) was significantly decreased in a dose-dependent manner, yielding commensurably elevated concentrations of intact AVP in the basolateral receiver fluid. In contrast, leupeptin (0.5 mM), a serine protease inhibitor, was without effect. These data, taken together, suggest that apically-presented AVP undergoes proteolysis (most likely by peptidases localized at apical cell membranes of alveolar epithelium). It does not appear that intact AVP traverses the alveolar epithelium by saturable processes but primarily via passive diffusional pathways. Thus, the high bioavailability reported in previous studies on the pulmonary instillation and/or delivery via aerosolization of AVP is likely due to passive diffusion of the peptide utilizing the large surface area available in the distal respiratory tract of the mammalian lung. Furthermore, inclusion of appropriate protease inhibitor may increase the overall transport of intact AVP across the alveolar epithelial barrier.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
I. Vavara, A. Machova, and I. Krejci. Antidiuretic action of 1-deamino-8-D-arginine-vasopressin in unanesthetized rats. J. Pharmacol. Exp. Ther. 188: 241–247 (1987).
J.M.M. van Bree, S. Tio, A.G. de Boer, M. Danhof, J.C. Verhoef, and D.D. Breimer. Transport of desglycinamidearginine vasopressin across the blood-brain barrier in rats as evaluated by the impulse response methodology. Pharm. Res. 7: 293–298 (1990).
J.M. Kelly, J.M. Abrahams, P.A. Phillips, F.A. Mendelsohn, Z. Grzonka, and C.I. Johnson. [125I]-[d(CH2)5, Sar7]AVP: a selective radioligand for V1 vasopressin receptors. J. Receptor Res. 9: 27–41 (1989).
H. Vilhardt and P. Bie. Antidiuretic response in conscious dogs following peroral administration of vasopressin and its analogs. Eur. J. Pharmacol. 93: 201–204 (1983).
H.G. Folkesson, B.R. Westrom, M. Dahlback, S. Lundin, and B.W. Karlsson. Passage of aerosolized BSA and the nonapeptide dDAVP via the respiratory tract in young and adult rats. Exp. Lung Res. 18: 595–614 (1992).
K. Morimoto, H. Yamahara, V.H.L. Lee, and K.J. Kim. Dipeptide transport across rat alveolar epithelial cell monolayers. Pharm. Res. 10: 1668–1674 (1993).
K.J. Kim, J.M. Cheek, and E.D. Crandall. Contribution of active Na+ and Cl− fluxes to net ion transport by alveolar epithelium. Respir. Physiol. 85: 245–256 (1991).
K.J. Kim, D.J. Suh, R.L. Lubman, S.I. Danto, Z. Borok, and E.D. Crandall. Ion fluxes across alveolar epithelial cell monolayers. J Tissue Culture Methods 14: 187–194 (1992).
L.G. Dobbs, M.C. Williams, and R. Gonzalez. An improved method for isolating type II cells in high yield and purity. Am. Rev. Respir. Dis. 134: 141–145 (1986).
J.M. Cheek, M.J. Evans, and E.D. Crandall. Type I cell-like morphology in tight alveolar epithelial monolayers. Exp. Cell Res. 184: 375–387 (1989).
S.I. Danto, S.M. Zabski, and E.D. Crandall. Reactivity of alveolar epithelial cells in primary culture with type I cell monoclonal antibodies. Am. J. Respir. Cell Mol. Biol. 6: 296–306 (1992).
Z. Grzonka, F. Kasprzykowski, L. Lubkowska, K. Darlak, T.A. Hahn, and A.F. Spatola. In vitro degradation of some arginine-vasopressin analogs by homogenates of rat kidney, liver, and serum. Peptide Res. 4: 270–274 (1991).
J.D. Funkhouser, S.D. Tangada, M. Jones, and R.D. Petersen. p146 type II alveolar epithelial antigen is identical to aminopeptidase N. Am. J. Physiol. 260: L274–L279 (1991).
A. Nagae, M. Abe, R.P. Becker, P.A. Deddish, R.A. Skidgel, and E.G. Erdoes. High concentration of carboxypeptidase M in lungs: presence of the enzyme in alveolar type I cells. Am. J. Respir. Cell Mol. Biol. 9: 221–229 (1993).
S. Lundin, S.G. Pierzynovski, B.R. Westroem, and B.I. Bengtsson. Biliary excretion of the vasopressin analog dDAVP after intraduodenal, intrajugular and intraportal administration in the conscious pig. Pharmacol. Toxicol. 68: 177–180 (1991).
J. Stehle, S. Reuss, R. Riemann, A. Seidel, and L. Vollrath. The role of arginine-vasopressin for pineal melatonin synthesis in the rat: involvement of vasopressinergic receptors. Neurosci. Lett. 123: 131–134 (1991).
M.J. Landon, D.K. Copas, E.A. Shiells, and J.M. Davison. Degradation of radiolabelled arginine vasopressin (125I-AVP) by the human placenta perfused in vitro. Brit. J. Obstet. and Gynecol. 95: 488–492 (1988).
A.L. Ungell, A. Andreasson, K. Lundin, and L. Utter. Effects of enzymatic inhibition and paracellular shunting on transport of vasopressin analogs in the rat. J. Pharm. Sci. 81: 640–645 (1992).
B. Matuszewska, G.G. Liversidge, F. Ryan, J. Dent, and P.L. Smith. In vitro study of intestinal absorption and metabolism of 8-L-arginine vasopressin and its analogs. Int. J. Pharm. 46: 111–120 (1988).
S. Lundin and P. Artursson. Absorption of a vasopressin analog, 1-deamino-8-D-arginine-vasopressin (dDAVP), in a human intestinal epithelial cell line, Caco-2. Int. J. Pharm. 64: 181–186 (1990).
B.V. Zlokovic, M.B. Segal, H. Davson, M.N. Liovac, S. Hyman, and J.G. McComb. Circulating neuroactive peptides and the blood-brain and blood-cerebrospinal fluid barriers. Endocrin. Exp. 24: 9–17 (1990).
H.G. Folkesson, B.R. Westroem, and B.W. Karlsson. Permeability of the respiratory tract to different-sized macromolecules after intratracheal instillation in young and adult rats. Acta. Physiol. Scand. 139: 347–354 (1990).
T. Morita, A. Yamamoto, M. Hashida, and H. Sezaki. Effects of various promoters on pulmonary absorption of drugs with different molecular weights. Chem. Pharm. Bull. 16: 259–262 (1993).
L.S. Schanker and J.A. Hemberger. Relation between molecular weight and pulmonary absorption rate of lipid insoluble compounds in neonatal and adults rats. Biochem. Pharmacol. 17: 2599–2601 (1983).
J.R. Pappenheimer and K.Z. Reiss. Contribution of solvent drag through intercellular junctions to absorption of nutrients by the small intestine of the rat. J. Membr. Biol. 100: 123–136 (1987).
P. Krugliak, D. Hollander, T.Y. Ma, D. Tran, U.D. Dadufalza, K.D. Katz, and K. Le. Mechanisms of polyethyleneglycol permeability of perfused rat intestine. Gastroenterology 97: 1164–1170 (1989).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yamahara, H., Morimoto, K., Lee, V.H.L. et al. Effects of Protease Inhibitors on Vasopressin Transport Across Rat Alveolar Epithelial Cell Monolayers. Pharm Res 11, 1617–1622 (1994). https://doi.org/10.1023/A:1018918022865
Issue Date:
DOI: https://doi.org/10.1023/A:1018918022865